跳至主要内容
临床试验/NCT03101293
NCT03101293已完成1 期

A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in Healthy Subjects

Neurocrine Biosciences1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2017年4月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
15
试验地点
1
主要终点
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831

研究概览

简要总结

The purpose of this study is to determine the pharmacokinetic (PK) of a single oral dose of TAK-831 400 milligram (mg) in the fasted state and to estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when administered as tablet formulation in healthy participants.

详细描述

The drug being tested in this study is called TAK-831. TAK-831 is being tested in healthy participants under fasting and fed conditions in order to determine the effect of food on the PK of single oral dose of TAK-831 tablet formulation. The study will enroll approximately 16 participants. Participants will be randomly and equally assigned (by chance, like flipping a coin) to 1 of the 2 treatment sequences following as:

  • TAK-831 400 mg Fasted + TAK-831 400 mg Fed
  • TAK-831 400 mg Fed + TAK-831 400 mg Fasted All participants will be asked to take single oral dose of TAK-831 tablet at the same time on Day 1 of each Intervention Period. This single center trial will be conducted in the United States. The overall time to participate in this study is 23 days. Participants will visit the clinic on Day -1 and remained confined until Day 3 of Intervention Period 1 and 2. A washout period of minimum 7 days will be maintained between the doses in each Intervention Period. Participants will make 3 visits to the clinic on Days 4, 6 and 8 on each Intervention Period and will be contacted by telephone 14 days after the last dose of study drug (Day 23) for a follow-up assessment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Weighs greater than or equal to (>=) 45 kilogram (kg) and has a body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m^2), inclusive at Screening.

排除标准

  • Has received TAK-831 in a previous clinical study.
  • Has poor peripheral venous access.
  • Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to first dose of study drug.
  • Has any dietary restrictions or preferences that may interfere with the conduct of the study.

研究组 & 干预措施

TAK-831 400 mg Fasted + TAK-831 400 mg Fed

Experimental

TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.

干预措施: TAK-831 (Drug)

TAK-831 400 mg Fed + TAK-831 400 mg Fasted

Experimental

TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.

干预措施: TAK-831 (Drug)

结局指标

主要结局

AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831

时间窗: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

Cmax: Maximum Observed Plasma Concentration for TAK-831

时间窗: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831

时间窗: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

次要结局

  • Percentage of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE)(Day 1)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验